Effects of myo-inositol plus alpha-lactalbumin in myo-inositol-resistant PCOS women.

ABSTRACT:

Background

Myo-inositol (MI), successfully used in polycystic ovary syndrome (PCOS), was administered with α-LA to exploit its action of favouring the passage of other molecules through biological barriers, and also considering its anti-inflammatory effect.

Methods

PCOS patients, according to the Rotterdam ESHRE-ASRM criteria, with anovulation and infertility > 1 year, were included in this open and prospective study. The preliminary phase was aimed at determining a set of MI-resistant PCOS patients. This treatment involved 2 g MI, taken twice per day by oral route, for three months. The Homeostasis Model Assessment (HOMA) index and MI plasma levels were measured. In the main phase, previously selected MI-resistant patients received the same daily amount of MI plus 50 mg α-L

SUBMITTER: Montanino Oliva M 

PROVIDER: S-EPMC5944130 | biostudies-literature | 2018 May

REPOSITORIES: biostudies-literature